Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBT: 2019-2024

Historic EBT for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to -$261.5 million.

  • Maravai Lifesciences Holdings' EBT rose 73.77% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$218.0 million, marking a year-over-year decrease of 149.47%. This contributed to the annual value of -$261.5 million for FY2024, which is 142.33% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its EBT stood at -$261.5 million for FY2024, which was down 142.33% from $617.7 million recorded in FY2023.
  • Maravai Lifesciences Holdings' 5-year EBT high stood at $617.7 million for FY2023, and its period low was -$261.5 million during FY2024.
  • Its 3-year average for EBT is $302.6 million, with a median of $551.5 million in 2022.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' EBT surged by 1,495.80% in 2020, and later crashed by 142.33% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBT (Yearly) stood at $81.7 million in 2020, then skyrocketed by 549.68% to $530.8 million in 2021, then rose by 3.90% to $551.5 million in 2022, then increased by 12.02% to $617.7 million in 2023, then tumbled by 142.33% to -$261.5 million in 2024.